Literature DB >> 18295208

Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour.

Sonia George1, Maarten van den Buuse, Su San Mok, Colin L Masters, Qiao-Xin Li, Janetta G Culvenor.   

Abstract

Up to 40% of Parkinson's disease patients suffer from anxiety, but little is known about the mechanisms involved. We used the elevated plus maze and open field test to evaluate groups of young adult mice expressing different levels of alpha-synuclein, including mice transgenic for human alpha-synuclein with the A53T mutation. Compared to alpha-synuclein knock-out mice and wild-type controls, alpha-synuclein A53T transgenic mice exhibited reduced anxiety-like behaviour by spending markedly greater amounts of time on the maze open arms and by a higher proportion of entries to the open arms. In the open field, transgenic mice showed a trend towards reduced locomotor habituation and increased thigmotaxis. These results indicate a possible role for alpha-synuclein in anxiety-like behaviours.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18295208     DOI: 10.1016/j.expneurol.2007.12.017

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  23 in total

1.  Age-dependent susceptibility to manganese-induced neurological dysfunction.

Authors:  Julie A Moreno; Elizabeth C Yeomans; Karin M Streifel; Bryan L Brattin; Robert J Taylor; Ronald B Tjalkens
Journal:  Toxicol Sci       Date:  2009-10-07       Impact factor: 4.849

Review 2.  Behavioral phenotyping of mouse models of Parkinson's disease.

Authors:  Tonya N Taylor; James G Greene; Gary W Miller
Journal:  Behav Brain Res       Date:  2010-03-06       Impact factor: 3.332

3.  Locomotor differences in mice expressing wild-type human α-synuclein.

Authors:  Genesys Giraldo; Mieu Brooks; Benoit I Giasson; Christopher Janus
Journal:  Neurobiol Aging       Date:  2018-02-06       Impact factor: 4.673

4.  Gender and manganese exposure interactions on mouse striatal neuron morphology.

Authors:  Jennifer L Madison; Michal Wegrzynowicz; Michael Aschner; Aaron B Bowman
Journal:  Neurotoxicology       Date:  2011-05-27       Impact factor: 4.294

5.  PET imaging of the influence of physiological and pathological α-synuclein on dopaminergic and serotonergic neurotransmission in mouse models.

Authors:  Elise Levigoureux; Caroline Bouillot; Thierry Baron; Luc Zimmer; Sophie Lancelot
Journal:  CNS Neurosci Ther       Date:  2018-05-20       Impact factor: 5.243

6.  α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment.

Authors:  Sonia George; Su San Mok; Milawaty Nurjono; Scott Ayton; David I Finkelstein; Colin L Masters; Qiao-Xin Li; Janetta G Culvenor
Journal:  J Mol Neurosci       Date:  2010-05-13       Impact factor: 3.444

Review 7.  Animal models of the non-motor features of Parkinson's disease.

Authors:  Kimberly McDowell; Marie-Françoise Chesselet
Journal:  Neurobiol Dis       Date:  2012-01-03       Impact factor: 5.996

8.  An unexpected improvement in spatial learning and memory ability in alpha-synuclein A53T transgenic mice.

Authors:  Qi Liu; YuYu Xu; WenPing Wan; ZeGang Ma
Journal:  J Neural Transm (Vienna)       Date:  2017-12-07       Impact factor: 3.575

9.  The clathrin-dependent localization of dopamine transporter to surface membranes is affected by α-synuclein.

Authors:  Haya Kisos; Tziona Ben-Gedalya; Ronit Sharon
Journal:  J Mol Neurosci       Date:  2013-09-19       Impact factor: 3.444

10.  Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice.

Authors:  Franz Marxreiter; Benjamin Ettle; Verena E L May; Hakan Esmer; Christina Patrick; Christine Lund Kragh; Jochen Klucken; Beate Winner; Olaf Riess; Jürgen Winkler; Eliezer Masliah; Silke Nuber
Journal:  Neurobiol Dis       Date:  2013-07-16       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.